Biotech News

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsEarnings

- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 - Selective EP300 degrader with potential to treat multiple myeloma (MM) and other hematological malignancies, tracking to IND in 2027 - Advancing a novel small

Related news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

Stock data

Close
1.78 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States